In this article we are going to address the topic of AM-1714 and explore its different facets. AM-1714 is a topic of great relevance in today's society, since it impacts various aspects of daily life. Throughout this article we will analyze its origin, its evolution over time and its influence in different areas. In addition, we will examine the different perspectives that exist around AM-1714, with the aim of offering a complete and enriching vision on this topic. Through a multidimensional approach, we aim to offer our readers a broad and detailed vision of AM-1714, with the purpose of encouraging reflection and debate around this topic that is so relevant today.
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H26O4 |
Molar mass | 354.446 g·mol−1 |
3D model (JSmol) | |
| |
|
AM-1714 (part of the AM cannabinoid series) is a drug that acts as a reasonably selective agonist of the peripheral cannabinoid receptor CB2, with sub-nanomolar affinity and 490x selectivity over the related CB1 receptor. In animal studies it has both analgesic and anti-allodynia effects. The 9-methoxy derivative AM-1710 has similar CB2 affinity but only 54x selectivity over CB1.[1][2]